| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Intervacc AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr4.20 |
| 52 Week High | kr10.46 |
| 52 Week Low | kr3.20 |
| Beta | 0.64 |
| 1 Month Change | 3.96% |
| 3 Month Change | 13.51% |
| 1 Year Change | -17.32% |
| 3 Year Change | -94.53% |
| 5 Year Change | -52.81% |
| Change since IPO | -45.45% |
Recent News & Updates
Recent updates
We're Keeping An Eye On Intervacc's (STO:IVACC) Cash Burn Rate
Oct 11
We Think Intervacc (STO:IVACC) Needs To Drive Business Growth Carefully
Feb 26We're Not Very Worried About Intervacc's (STO:IVACC) Cash Burn Rate
Sep 03We're Not Worried About Intervacc's (STO:IVACC) Cash Burn
Apr 28Here's Why We're Not At All Concerned With Intervacc's (STO:IVACC) Cash Burn Situation
Dec 15It Looks Like The CEO Of Intervacc AB (publ) (STO:IVACC) May Be Underpaid Compared To Peers
Jun 01We Think Intervacc (STO:IVACC) Can Easily Afford To Drive Business Growth
May 17Intervacc AB (publ) (STO:IVACC) Insiders Have Been Selling
Feb 28We Think Intervacc (STO:IVACC) Can Easily Afford To Drive Business Growth
Feb 01When Will Intervacc AB (publ) (STO:IVACC) Become Profitable?
Jan 06Is Intervacc AB (publ)'s (STO:IVACC) Shareholder Ownership Skewed Towards Insiders?
Dec 10Shareholder Returns
| IVACC | SE Biotechs | SE Market | |
|---|---|---|---|
| 7D | -6.5% | -2.3% | 0.5% |
| 1Y | -17.3% | 4.0% | 18.6% |
Return vs Industry: IVACC underperformed the Swedish Biotechs industry which returned 4% over the past year.
Return vs Market: IVACC underperformed the Swedish Market which returned 18.6% over the past year.
Price Volatility
| IVACC volatility | |
|---|---|
| IVACC Average Weekly Movement | 8.5% |
| Biotechs Industry Average Movement | 9.5% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in SE Market | 13.2% |
| 10% least volatile stocks in SE Market | 3.5% |
Stable Share Price: IVACC's share price has been volatile over the past 3 months.
Volatility Over Time: IVACC's weekly volatility has decreased from 14% to 8% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1983 | 15 | Jonas Sohlman | www.intervacc.se |
Intervacc AB (publ) develops novel veterinary vaccines for animals in Sweden. The company’s product pipeline includes Stangvac, a vaccine against equine strangles for horses; INV274, antigens for a vaccine against Strep. suis for the treatment of piglets; and INV412, a multi-component vaccine to protect against several bacteria which cause mastitis for treating cows.
Intervacc AB (publ) Fundamentals Summary
| IVACC fundamental statistics | |
|---|---|
| Market cap | kr318.09m |
| Earnings (TTM) | -kr102.76m |
| Revenue (TTM) | kr8.94m |
35.6x
P/S Ratio-3.1x
P/E RatioIs IVACC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IVACC income statement (TTM) | |
|---|---|
| Revenue | kr8.94m |
| Cost of Revenue | kr23.11m |
| Gross Profit | -kr14.18m |
| Other Expenses | kr88.59m |
| Earnings | -kr102.76m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 30, 2024
| Earnings per share (EPS) | -1.36 |
| Gross Margin | -158.65% |
| Net Profit Margin | -1,150.01% |
| Debt/Equity Ratio | 0.06% |
How did IVACC perform over the long term?
See historical performance and comparison